Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last C$11.75 CAD
Change Today 0.00 / 0.00%
Volume 5.8K
COM On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 2:02 PM 07/30/15 All times are local (Market data is delayed by at least 15 minutes).

cardiome pharma corp (COM) Snapshot

Open
C$11.75
Previous Close
C$11.75
Day High
C$11.90
Day Low
C$11.74
52 Week High
01/21/15 - C$13.80
52 Week Low
08/6/14 - C$6.62
Market Cap
197.1M
Average Volume 10 Days
3.6K
EPS TTM
C$-1.14
Shares Outstanding
16.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CARDIOME PHARMA CORP (COM)

Related News

No related news articles were found.

cardiome pharma corp (COM) Related Businessweek News

No Related Businessweek News Found

cardiome pharma corp (COM) Details

Cardiome Pharma Corp., a specialty pharmaceutical company, engages in the development and commercialization of cardiovascular therapies that enhance the life and health of patients from heart diseases. It offers BRINAVESS (vernakalant IV) for the conversion of recent onset atrial fibrillation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in acute coronary syndrome patients. It has operations in Canada, the United States, and Europe. The company was formerly known as Nortran Pharmaceuticals Inc. and changed its name to Cardiome Pharma Corp. in June 2001. Cardiome Pharma Corp. was founded in 1986 and is based in Vancouver, Canada.

Founded in 1986

cardiome pharma corp (COM) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: C$650.0K
Chief Financial Officer
Total Annual Compensation: C$275.0K
Chief Operating Officer
Total Annual Compensation: C$240.0K
Corporate General Counsel
Total Annual Compensation: C$248.5K
Compensation as of Fiscal Year 2014.

cardiome pharma corp (COM) Key Developments

Cardiome Pharma Corp. to Initiate BRINAVESS Phase I Study in China

Cardiome Pharma Corp. announced that it's Chinese development and commercialization partner, Eddingpharm, plans to initiate a Phase 1 study for BRINAVESS to support regulatory approval in China. The study will be conducted in healthy volunteers. Other details of the study were not disclosed. If BRINAVESS successfully completes Phase 1, Eddingpharm anticipates initiating a pivotal Phase 3 study by year end. Cardiome and Eddingpharm entered into a BRINAVESS development and commercialization agreement in China, Taiwan, Macau and Hong Kong on December 19, 2014. Under the terms of the agreement, Eddingpharm made an upfront payment of USD 1.0 Million to Cardiome and agreed to specific annual commercial goals for BRINAVESS.

Cardiome Submits Supplemental New Drug Submission for AGGRASTAT to Health Canada

Cardiome Pharma Corp. announced that it has submitted a Supplemental New Drug Submission (sNDS) to Health Canada's Therapeutic Products Directorate for AGGRASTAT® (tirofiban hydrochloride). The sNDS includes data to support: 1) High Dose Bolus administration of AGGRASTAT; and 2) an indication expansion for the reduction of major cardiovascular events in patients with acute myocardial infarction (STEMI) intended for primary PCI. AGGRASTAT, in combination with heparin and ASA is currently indicated in Canada for the management of patients with unstable angina or non-Q-wave myocardial infarction, including patients who may subsequently undergo PTCA (percutaneous transluminal coronary angioplasty), to decrease the rate of refractory ischemic conditions, new myocardial infarction and death. AGGRASTAT is a reversible non-peptide antagonist of fibrinogen binding to the GP IIb/IIIa receptor, the major platelet surface receptor involved in platelet aggregation. When administered intravenously, tirofiban inhibits ex vivo platelet aggregation in a dose and concentration dependent manner. Cardiome acquired Canadian AGGRASTAT commercialization rights through its acquisition of Correvio LLC in November 2013.

Cardiome Pharma Corp. Announces Executive Appointments

Cardiome Pharma Corp. at its AGM held on June 22, 2015, approved the appointment of Mark H. Corrigan and Arthur H. Willms as Directors. Dr. Corrigan is currently the Chairman of the Board of Directors at Epirus Biopharmaceuticals Inc. and was a former Board member of Cubist Pharmaceuticals Inc. W. James O'Shea will serve as Cardiome's new Chairman of the Board of Directors, effective immediately.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
COM:CN C$11.75 CAD 0.00

COM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Eli Lilly & Co $84.55 USD -0.54
Medicure Inc C$2.95 CAD -0.08
Merck & Co Inc $58.74 USD +0.20
Medicines Co/The $30.23 USD -0.72
View Industry Companies
 

Industry Analysis

COM

Industry Average

Valuation COM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 5.4x
Price/Book 10.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 4.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CARDIOME PHARMA CORP, please visit www.cardiome.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.